3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
fludarabine phosphate
31
Cyclophosphamide
27
Mycophenolic Acid
22
Whole-Body Irradiation
21
Tacrolimus
21
ruxolitinib
19
Peripheral Blood Stem Cell Transplantation
19
Busulfan
19
Antilymphocyte Serum
16
fludarabine
14
Melphalan
12
Methotrexate
11
Cyclosporine
10
thymoglobulin
9
Cord Blood Stem Cell Transplantation
7
Sirolimus
6
Radiotherapy
6
Etoposide
6
Azacitidine
6
Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
4
pomalidomide
3
parsaclisib
3
Surveys and Questionnaires
3
Rituximab
3
Prednisone
3
Filgrastim
3
Cytarabine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Primary Myelofibrosis
×
pertuzumab
×
Clear all
No trials found.